Emerging biological therapies to treat acute lymphoblastic leukemia.
about
A phase I trial of NK-92 cells for refractory hematological malignancies relapsing after autologous hematopoietic cell transplantation shows safety and evidence of efficacy.Efficacy and safety of bispecific T-cell engager blinatumomab and the potential to improve leukemia-free survival in B-cell acute lymphoblastic leukemia.New targeted therapies for relapsed pediatric acute lymphoblastic leukemia.
P2860
Emerging biological therapies to treat acute lymphoblastic leukemia.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Emerging biological therapies to treat acute lymphoblastic leukemia.
@en
Emerging biological therapies to treat acute lymphoblastic leukemia.
@nl
type
label
Emerging biological therapies to treat acute lymphoblastic leukemia.
@en
Emerging biological therapies to treat acute lymphoblastic leukemia.
@nl
prefLabel
Emerging biological therapies to treat acute lymphoblastic leukemia.
@en
Emerging biological therapies to treat acute lymphoblastic leukemia.
@nl
P2860
P1476
Emerging biological therapies to treat acute lymphoblastic leukemia.
@en
P2093
Françoise Huguet
Suzanne Tavitian
P2860
P304
P356
10.1080/14728214.2016.1257606
P407
P577
2016-11-08T00:00:00Z